SCHOTT PHARMA AG& CO KGAA (1SXP.DE) Stock Fundamental Analysis
Europe - FRA:1SXP - DE000A3ENQ51 - Common Stock
18.4 EUR
+0.08 (+0.44%)
1SXP gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 18 industry peers in the Life Sciences Tools & Services industry. While 1SXP has a great profitability rating, there are some minor concerns on its financial health. 1SXP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
1SXP had positive earnings in the past year.
1SXP had a positive operating cash flow in the past year.
In the past 5 years 1SXP has always been profitable.
Each year in the past 5 years 1SXP had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 9.62%, 1SXP belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
The Return On Equity of 1SXP (17.03%) is better than 83.33% of its industry peers.
1SXP's Return On Invested Capital of 13.86% is amongst the best of the industry. 1SXP outperforms 88.89% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for 1SXP is in line with the industry average of 13.84%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROIC | 13.86% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
1.3 Margins
The Profit Margin of 1SXP (15.07%) is better than 83.33% of its industry peers.
In the last couple of years the Profit Margin of 1SXP has remained more or less at the same level.
1SXP's Operating Margin of 19.41% is fine compared to the rest of the industry. 1SXP outperforms 77.78% of its industry peers.
1SXP's Operating Margin has improved in the last couple of years.
1SXP has a worse Gross Margin (33.73%) than 61.11% of its industry peers.
1SXP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% |
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), 1SXP is creating value.
Compared to 1 year ago, 1SXP has more shares outstanding
Compared to 1 year ago, 1SXP has about the same debt to assets ratio.
2.2 Solvency
The Debt to FCF ratio of 1SXP is 1.69, which is an excellent value as it means it would take 1SXP, only 1.69 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 1.69, 1SXP belongs to the top of the industry, outperforming 94.44% of the companies in the same industry.
1SXP has a Debt/Equity ratio of 0.09. This is a healthy value indicating a solid balance between debt and equity.
1SXP has a Debt to Equity ratio of 0.09. This is amongst the best in the industry. 1SXP outperforms 88.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Altman-Z | N/A |
ROIC/WACC1.65
WACC8.38%
2.3 Liquidity
A Current Ratio of 1.57 indicates that 1SXP should not have too much problems paying its short term obligations.
1SXP has a Current ratio of 1.57. This is in the better half of the industry: 1SXP outperforms 77.78% of its industry peers.
A Quick Ratio of 1.16 indicates that 1SXP should not have too much problems paying its short term obligations.
The Quick ratio of 1SXP (1.16) is better than 72.22% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 |
3. Growth
3.1 Past
The earnings per share for 1SXP have decreased by -3.00% in the last year.
The Earnings Per Share has been growing by 13.90% on average over the past years. This is quite good.
The Revenue has been growing slightly by 2.86% in the past year.
The Revenue has been growing by 13.84% on average over the past years. This is quite good.
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
3.2 Future
The Earnings Per Share is expected to grow by 11.13% on average over the next years. This is quite good.
Based on estimates for the next years, 1SXP will show a quite strong growth in Revenue. The Revenue will grow by 8.14% on average per year.
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 18.97, 1SXP is valued on the expensive side.
72.22% of the companies in the same industry are more expensive than 1SXP, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.07, 1SXP is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 15.73, the valuation of 1SXP can be described as correct.
Based on the Price/Forward Earnings ratio, 1SXP is valued a bit cheaper than 77.78% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 34.08, 1SXP is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.97 | ||
| Fwd PE | 15.73 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of 1SXP indicates a somewhat cheap valuation: 1SXP is cheaper than 72.22% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, 1SXP is valued a bit more expensive than the industry average as 72.22% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 54.34 | ||
| EV/EBITDA | 10.56 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates 1SXP does not grow enough to justify the current Price/Earnings ratio.
1SXP has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)5.84
PEG (5Y)N/A
EPS Next 2Y8.71%
EPS Next 3Y10.5%
5. Dividend
5.1 Amount
With a yearly dividend of 0.85%, 1SXP is not a good candidate for dividend investing.
In the last 3 months the price of 1SXP has falen by -22.54%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
1SXP's Dividend Yield is a higher than the industry average which is at 0.74.
Compared to an average S&P500 Dividend Yield of 2.44, 1SXP's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.85% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
16.33% of the earnings are spent on dividend by 1SXP. This is a low number and sustainable payout ratio.
DP16.33%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
FRA:1SXP (11/21/2025, 5:29:10 PM)
18.4
+0.08 (+0.44%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners19.52%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap2.77B
Revenue(TTM)975.68M
Net Income(TTM)147.00M
Analysts78.95
Price Target29.97 (62.88%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.85% |
Yearly Dividend0.15
Dividend Growth(5Y)N/A
DP16.33%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)2.21%
Min EPS beat(2)-1.05%
Max EPS beat(2)5.48%
EPS beat(4)1
Avg EPS beat(4)-5.25%
Min EPS beat(4)-14.42%
Max EPS beat(4)5.48%
EPS beat(8)4
Avg EPS beat(8)6.65%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-2.27%
Max Revenue beat(2)1.75%
Revenue beat(4)1
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-5.31%
Max Revenue beat(4)1.75%
Revenue beat(8)3
Avg Revenue beat(8)0.96%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.52%
PT rev (3m)-1.16%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.97%
EPS NY rev (1m)-1.65%
EPS NY rev (3m)-1.61%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.79%
Revenue NY rev (1m)-0.3%
Revenue NY rev (3m)-2.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 18.97 | ||
| Fwd PE | 15.73 | ||
| P/S | 2.84 | ||
| P/FCF | 54.34 | ||
| P/OCF | 13.58 | ||
| P/B | 3.21 | ||
| P/tB | 3.33 | ||
| EV/EBITDA | 10.56 |
EPS(TTM)0.97
EY5.27%
EPS(NY)1.17
Fwd EY6.36%
FCF(TTM)0.34
FCFY1.84%
OCF(TTM)1.35
OCFY7.36%
SpS6.48
BVpS5.73
TBVpS5.53
PEG (NY)5.84
PEG (5Y)N/A
Graham Number11.18
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.62% | ||
| ROE | 17.03% | ||
| ROCE | 16.98% | ||
| ROIC | 13.86% | ||
| ROICexc | 14.4% | ||
| ROICexgc | 14.81% | ||
| OM | 19.41% | ||
| PM (TTM) | 15.07% | ||
| GM | 33.73% | ||
| FCFM | 5.23% |
ROA(3y)11.07%
ROA(5y)11.97%
ROE(3y)19.57%
ROE(5y)21.49%
ROIC(3y)15.67%
ROIC(5y)17.02%
ROICexc(3y)16.17%
ROICexc(5y)17.75%
ROICexgc(3y)16.77%
ROICexgc(5y)18.76%
ROCE(3y)19.22%
ROCE(5y)20.88%
ROICexgc growth 3Y-8.55%
ROICexgc growth 5YN/A
ROICexc growth 3Y-7.4%
ROICexc growth 5YN/A
OM growth 3Y4.06%
OM growth 5YN/A
PM growth 3Y0.29%
PM growth 5YN/A
GM growth 3Y-1.12%
GM growth 5YN/A
F-Score5
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.09 | ||
| Debt/FCF | 1.69 | ||
| Debt/EBITDA | 0.3 | ||
| Cap/Depr | 204% | ||
| Cap/Sales | 15.68% | ||
| Interest Coverage | 11.79 | ||
| Cash Conversion | 77.17% | ||
| Profit Quality | 34.69% | ||
| Current Ratio | 1.57 | ||
| Quick Ratio | 1.16 | ||
| Altman-Z | N/A |
F-Score5
WACC8.38%
ROIC/WACC1.65
Cap/Depr(3y)291.66%
Cap/Depr(5y)279.8%
Cap/Sales(3y)17.76%
Cap/Sales(5y)16.62%
Profit Quality(3y)26.94%
Profit Quality(5y)27.76%
High Growth Momentum
Growth
EPS 1Y (TTM)-3%
EPS 3Y13.9%
EPS 5YN/A
EPS Q2Q%-3.23%
EPS Next Y3.25%
EPS Next 2Y8.71%
EPS Next 3Y10.5%
EPS Next 5Y11.13%
Revenue 1Y (TTM)2.86%
Revenue growth 3Y13.84%
Revenue growth 5YN/A
Sales Q2Q%1.13%
Revenue Next Year2.31%
Revenue Next 2Y5.51%
Revenue Next 3Y7.02%
Revenue Next 5Y8.14%
EBIT growth 1Y11.76%
EBIT growth 3Y18.46%
EBIT growth 5YN/A
EBIT Next Year46.93%
EBIT Next 3Y24.15%
EBIT Next 5Y18.78%
FCF growth 1Y-26.72%
FCF growth 3Y33.53%
FCF growth 5YN/A
OCF growth 1Y-5.2%
OCF growth 3Y19.39%
OCF growth 5YN/A
SCHOTT PHARMA AG& CO KGAA / 1SXP.DE FAQ
Can you provide the ChartMill fundamental rating for SCHOTT PHARMA AG& CO KGAA?
ChartMill assigns a fundamental rating of 6 / 10 to 1SXP.DE.
What is the valuation status of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) stock?
ChartMill assigns a valuation rating of 4 / 10 to SCHOTT PHARMA AG& CO KGAA (1SXP.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for SCHOTT PHARMA AG& CO KGAA?
SCHOTT PHARMA AG& CO KGAA (1SXP.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for 1SXP stock?
The Price/Earnings (PE) ratio for SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 18.97 and the Price/Book (PB) ratio is 3.21.
Is the dividend of SCHOTT PHARMA AG& CO KGAA sustainable?
The dividend rating of SCHOTT PHARMA AG& CO KGAA (1SXP.DE) is 3 / 10 and the dividend payout ratio is 16.33%.